Genetronics Biomedical (GEB) Initiates Pancreatic Cancer Clinical Trial Using Its MedPulser Tumor Ablation System
10/19/2005 5:12:53 PM
SAN DIEGO--(BUSINESS WIRE)--March 1, 2005--
Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that it has initiated a Phase I clinical trial to treat pancreatic cancer using its MedPulser(R) Tumor Ablation System. The FDA has granted Genetronics orphan designation for this indication.
The primary endpoint of this FDA-approved study is to determine the safety profile of the MedPulser(R) electroporation therapy in conjunction with intralesionally-injected bleomycin for the treatment of unresectable or incurable locally advanced pancreatic cancer. The secondary endpoints are to assess objective tumor response, patient pain, and weight loss over 24 weeks following electroporation therapy. Genetronics aims to complete enrollment of up to 12 patients by the end of 2005.